Poloxamer P85 increases anticancer activity of schiff base against prostate cancer in vitro and in vivo

Basit Öğe Kaydı
dc.authorid0000-0002-6242-3709
dc.authorid0000-0002-9476-8488
dc.authorid0000-0001-6494-8923
dc.contributor.authorDemirci, Selami
dc.contributor.authorDoğan, Ayşegül
dc.contributor.authorTürkmen Bacak, Neşe
dc.contributor.authorTelci, Dilek
dc.contributor.authorÇağlayan, Ahmet Burak
dc.contributor.authorBeker, Mustafa Çağlar
dc.contributor.authorKılıç, Ertuğrul
dc.contributor.authorÖzkan, Ferda
dc.contributor.authorDede, Bülent
dc.contributor.authorŞahin, Fikrettin
dc.date.accessioned10.07.201910:49:13
dc.date.accessioned2019-07-10T19:35:41Z
dc.date.available10.07.201910:49:14
dc.date.available2019-07-10T19:35:41Z
dc.date.issued2017
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Fizyoloji Ana Bilim Dalı
dc.description.abstractProstate cancer is the second most common cancer among men and the leading cause of death after lung cancer. Development of hormone-refractory disease is a crucial step for prostate cancer progression for which an effective treatment option is currently unavailable. Therefore, there is a need for new agents that can efficiently target cancer cells, decrease tumor growth, and thereby extend the survival of patients in late-stage castration-resistant prostate cancer. In the current study, a novel heterodinuclear copper(II)Mn(II) Schiff base complex combined with P85 was used to evaluate anticancer activity against prostate cancer in vitro and in vivo. Cell proliferation and cytotoxicity were evaluated by cell viability, gene, and protein expression assays in vitro. Results showed that the heterodinuclear copper(II)Mn(II) complex-P85 combination decreased cell proliferation by upregulating the apoptotic gene expressions and blocking the cell proliferation-related pathways. Tramp-C1-injected C57/B16 mice were used to mimic a prostate cancer model. Treatment combination of Schiff base complex and P85 significantly enhanced the cellular uptake of chemicals (by blocking the drug transporters and increased life time), suppressed tumor growth, and decreased tumor volume steadily over the course of the experiments. Overall, heterodinuclear copper(II)Mn(II) complex-P85 showed remarkable anticancer activity against prostate cancer in in vitro and in vivo.
dc.identifier.citationDemirci, S., Doğan, A., Türkmen Bacak, N., Telci, D., Çağlayan, A. B., Beker, M. Ç. ... Şahin, F. (2017) Poloxamer P85 increases anticancer activity of schiff base against prostate cancer in vitro and in vivo. Anti-Cancer Drugs, 28(8), 869-879. https://dx.doi.org/10.1097/CAD.0000000000000528
dc.identifier.doi10.1097/CAD.0000000000000528
dc.identifier.endpage879
dc.identifier.issn0959-4973
dc.identifier.issn1473-5741
dc.identifier.issue8
dc.identifier.scopusqualityQ2
dc.identifier.startpage869
dc.identifier.urihttps://hdl.handle.net/20.500.12511/901
dc.identifier.urihttps://dx.doi.org/10.1097/CAD.0000000000000528
dc.identifier.volume28
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofAnti-Cancer Drugsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCastration-Resistant Prostate Cancer
dc.subjectP85
dc.subjectPoloxamer
dc.subjectProstate Cancer
dc.subjectSchiff Base
dc.titlePoloxamer P85 increases anticancer activity of schiff base against prostate cancer in vitro and in vivo
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Demirci-Selami(2017).pdf
Boyut:
697.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu